High-risk human papillomaviruses L1 gene isolates identified in Western Kazakhstan

Saule K. Balmagambetova 1 * , Elena V. Zholdybayeva 2, Oxana V. Zavalennaya 3, Ainur Amanzholkyzy 4, Victoria I. Kononets 5, Gulmira M. Zharmakhanova 5, Nadiar M. Mussin 6, Lazzat M. Zhamaliyeva 7, Nurgul M. Kereyeva 1
More Detail
1 Department of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
2 Shared laboratory, National Center for Biotechnology, Astana, Kazakhstan
3 PCR laboratory, Scientific-Production Center, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
4 Department of Physiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
5 Department of Natural Science Disciplines, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
6 Department of Transplantology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
7 Department of Family Medicine, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 21, Issue 1, pp. 26-34. https://doi.org/10.23950/jcmk/14274
OPEN ACCESS 412 Views 260 Downloads
Download Full Text (PDF)
Author Contributions
Conceptualization, S. B. and E. Z.; methodology, S. B., E. Z. and O. Z.; validation, A. A. and G. Z.; formal analysis, V. K., G. Z., and N. K.; investigation, S. B., E. Z., and O. Z.; resources, A. A. and L. Z.; data curation, O. Z., V. K. and G. Z.; writing – original draft preparation, S. B.; writing – review and editing, S. B., E. Z. and N. M.; visualization, E. Z.; supervision, S. B.; project administration, N. M.; funding acquisition, L. Z. and N. K. The authors have read and agreed to the published version of the manuscript.

ABSTRACT

Kazakhstani researchers reported a significant prevalence of highly carcinogenic human papillomavirus types in the country.
The article aimed to present HPV L1 gene sequencing developments in women affected with cervical cancer throughout the western part of Kazakhstan with provided findings on the geographic pathways of obtained isolates.
Methods. The HPV L1 gene was amplified using the consensus primers MY09HPV 5’-CGTCCMARRGGAWACTGATC-3’ and MY11HPV 5’ – GCMCAGGGWCATAAYAATGG-3’.  The purified DNA was used as the target for direct nucleotide sequencing. Phylogenetic analyses were conducted using the MegAlign program from the LASERGENE software package (version 6.0; DNA star, Madison, WI) and with MEGA version 5.0 software. A multiple alignment was created through Clustal W software, and the neighbor-joining method was used to construct the phylogenetic tree.
Results. Of 70 HPV samples transported to the Astana shared laboratory for gene L1 sequencing, only ten appeared fit to obtain isolates (14.3%). The viral load of the samples ranged from 3.3 to 8.2, and the range of DNA concentration was from 8.16 to 69.6 ng/uL. HPV16 unique Kazakhstani isolate from Aktobe, having its own branch, and not yet registered in the world genebank, was revealed. An isolate of potentially carcinogenic HPV53 forming a remote cluster with KF436822/1, KU951264.1 - Southwest China, and 97% identity with EU056643.1 - Ireland, and acted as a single agent for invasive cervical cancer was identified.
In general, the sequencing findings indicate the variety of ways for HPV pervasion into the western region of Kazakhstan: North and South America, Europe, and Asia.
The study was recorded in the ISRCTN registry, No. 7154910, 02/01/2018.
Keywords: Human papillomavirus, gene sequencing, isolates, gene L1, cervical cancer, western Kazakhstan.

CITATION

Balmagambetova SK, Zholdybayeva EV, Zavalennaya OV, Amanzholkyzy A, Kononets VI, Zharmakhanova GM, et al. High-risk human papillomaviruses L1 gene isolates identified in Western Kazakhstan. J CLIN MED KAZ. 2024;21(1):26-34. https://doi.org/10.23950/jcmk/14274

REFERENCES

  • Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021; 21(1): 894. https://doi.org/10.1186/s12889-021-10907-5.
  • zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology. 2009; 384(2): 260-5. https://doi.org/10.1016/j.virol.2008.11.046.
  • Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
  • Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009; 4: 17-29. https://doi.org/10.1186/1750-9378-4-8.
  • Halec G, Alemany L, Lloveras B, Schmitt M, et al. Retrospective International Survey and HPV Time Trends Study Group. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 234: 441-51. ttps://doi.org/10.1002/path.4405.
  • McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol 2022; 20(2): 95–108. https://doi.org/10.1038/s41579-021-00617-5.
  • Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review. Asian Pac J Cancer 2018; 19(2): 319-24. https://doi.org/10.1111/ecc.13207.
  • Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, & Poljak M. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine 2013; 31 Suppl 7: H46–H58. https://doi.org/10.1016/j.vaccine.2013.06.043.
  • De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013; 31 Suppl 5: F32-46. https://doi.org/10.1016/j.vaccine.2012.07.092.
  • European Cancer Organisation. Putting HPV on the Map: The State of HPV Prevention Programmes in the WHO European Region. Available at: [https://www.europeancancer.org/resources/256:hpv-prevention-programmes.html] (Accessed 27 Apr 2022.)
  • Balmagambetova SK, Tinelli A, Urazayev ON, Sakieva KZ, Koyshybaev AK, Zholmukhamedova DA, et al. HPV Types Distribution in General Female Population and in Women Diagnosed with Cervical Cancer Across Western Kazakhstan. Asian Pac J Cancer 2019; 20(4): 1089-96. https://doi.org/10.31557/APJCP.2019.20.4.1089.
  • Babi A, Issa T, Issanov A, Akilzhanova A, Nurgaliyeva K, Abugalieva Z, et al. Prevalence of high-risk human papillomavirus infection among Kazakhstani women attending gynecological outpatient clinics. Int J Infect Dis 2021; 109: 8-16. https://doi.org/10.1016/j.ijid.2021.06.006.
  • Aimagambetova G, Azizan A. Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: a Review. Asian Pac J Cancer Prev 2018; 19(5): 1175-80. https://doi.org/10.22034/APJCP.2018.19.5.1175.
  • Niyazmetova L, Aimagambetova G, Stambekova N, et al. Application of molecular genotyping to determine prevalence of HPV strains in pap smears of Kazakhstan women. Int J Infect Dis 2016; 54: 85-8. https://doi.org/10.1016/j.ijid.2016.11.410.
  • Aimagambetova G, Chan CK, Ukybassova T, Imankulova B, Balykov A, Kongrtay K, et al. Cervical cancer screening and prevention in Kazakhstan and Central Asia. J Med Screen. 2021; 28(1): 48-50. https://doi.org/10.1177/0969141320902482.
  • Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Kazakhstan. Summary Report 22 October 2021. [Date Accessed]
  • Aimagambetova G, Babi A, Issa T, Issanov A. What Factors Are Associated with Attitudes towards HPV Vaccination among Kazakhstani Women? Exploratory Analysis of Cross-Sectional Survey Data. Vaccines (Basel). 2022; 10(5): 824. https://doi.org/10.3390/vaccines10050824.
  • Pal A, & Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol 2020; 10: 3116. https://doi.org/10.3389/fmicb.2019.03116.
  • Van Doorslaer K. Revisiting Papillomavirus Taxonomy: A Proposal for Updating the Current Classification in Line with Evolutionary Evidence. Viruses 2022; 14(10): 2308. https://doi.org/10.3390/v14102308.
  • Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, Malik S, Kumar L, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol 2022; 174: 103675. https://doi.org/10.1016/j.critrevonc.2022.103675.
  • Vonsky M, Shabaeva M, Runov A, Lebedeva N, Chowdhury S, Palefsky JM, & Isaguliants M. Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy. Biochemistry. Biokhimiia 2019; 84(7): 782–799. https://doi.org/10.1134/S0006297919070095.
  • Sayers EW, Cavanaugh M, Clark K, Ostell J, Pruitt KD, & Karsch-Mizrachi I. GenBank. Nucleic Acids Res 2020; 48(D1): D84–D86. https://doi.org/10.1093/nar/gkz956.
  • Mane A, Patil L, Limaye S, Nirmalkar A, Kulkarni-Kale U. Characterization of major capsid protein (L1) variants of Human papillomavirus type 16 by cervical neoplastic status in Indian women: Phylogenetic and functional analysis. J Med Virol 2020; 92(8): 1303-08. https://doi.org/10.1002/jmv.25675.
  • Shen-Gunther J, Cai H, Zhang H and Wang Y. Abundance of HPV L1 Intra-Genotype Variants With Capsid Epitopic Modifications Found Within Low- and High-Grade Pap Smears With Potential Implications for Vaccinology. Front Genet 2019; 10: 489. https://doi.org/10.3389/fgene.2019.00489.
  • Bekmukhambetov YZ, Mynbaev OA, Tinelli A, Balmagambetova SK, Koyshybaev AК, Urazayev ON, Ismagulova EK, et al. Human Papillomavirus related issues in western Kazakhstan: Protocol for a comprehensive study. Rus Open Med J. 2018; 7(4): e0408. https://doi.org/10.15275/rusomj.2018.0408.
  • Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int J Mol Sci. 2022; 23(9): 4943. doi: 10.3390/ijms23094943. Erratum in: Int J Mol Sci. 2022; 23(14). https://doi.org/10.3390/ijms23094943.
  • Oumeslakht L, Ababou M, Badaoui B, Qmichou Z. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency. Gene 2021; 782:145533. https://doi.org/10.1016/j.gene.2021.145533.
  • Nelson CW, & Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res 2023; 15: 200258. https://doi.org/10.1016/j.tvr.2023.200258.
  • Sait K, Turki R, Abuzenadah AM, Jiffiri OH, Bohmaidah A, Sohrab SS. Genetic diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical specimens of women in Saudi Arabia. Saudi J Biol Sci. 2019; 26(2): 317-24. https://doi.org/10.1016/j.sjbs.2018.05.005.